Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker

Table 1 Clinicopathological and laboratory information for patients selected for RT-qPCR analysis

Parameter		HGSC^a, n = 35	CCC^a, n = 19
Age; mean ± SD (range)		64.0 ± 11.3 (45–87)	63.9 ± 15.3 (28–83)
Preoperative CA125 (kU/L); mean ± SD		3023 ± 4129	1438 ± 2198
FIGO stage	I	0	10
	II	0	3
	III	25	5
	IV	10	1
Residual disease	0 cm	3	13
	<2 cm	9	4
	>2 cm	23	2
Start of chemotherapy (days after surgery); mean ± SD		27.7 ± 11.6	25.7 ± 13.8
CA125 response^b	Yes	31	15
CA125 response^b	No	1	0
Optimal CA125 normalization^b	Yes	20	13
Optimal CA125 normalization^b	No	14	3
Median time (months) until progression (95% CI)		10 (7–13)	NA^c
Median time (months) until death (95% CI)		26 (18–34)	105 (35–175)
Status at last follow-up^d	NED	1	11
	AWD	1	1
	DOD	33	6
	DOUC	0	1

^aHGSC: High-grade serous ovarian carcinoma; CCC: Clear cell ovarian carcinoma.
^bAccording to the GCIG criteria (http://www.gcig.igcs.org). For HGSC: Two patients who received no postoperative treatment due to poor general condition, one patient with preoperative CA125 < 70; For CCC: One patient who received no postoperative treatment due to poor condition, three patients with preoperative CA125 < 70.
^cCould not be calculated since the Kaplan-Meier survival curve stays above 50%.
^dNED = No evidence of disease; AWD = Alive with disease; DOD = Dead of disease; DOUC = Dead of unrelated cause.

ISSN: 1471-2407